Summary
ZYMVOL is start-up specialized in computer-driven biocatalyst discovery and development for the pharmaceutical and fine chemical industry. We harness the power of high-performance computing to identify and optimize custom-made biocatalysts that deliver additional value.
Biocatalysts are enzymes that accelerate industrial chemical reactions and have multiple applications for the synthesis of chemical compounds. Engineered enzymes can provide improved performance, representing a unique advantage. The protein engineering market is a fast-growing business estimated to reach 2.67B€ by 2024 (CARG +15%).
The main obstacle today to performance enhanced biocatalysts is that current enzyme engineering processes rely on slow and costly experimental tests with uncertain outcomes. Our in-silico engineering platform can rapidly find thousands of enzyme variants delivering reliable predictions, that allow to replace up to 90% of experimental tests, making the enzyme development cost (10-fold lower) and time (cut by 50%) effective.
ZYMVOL aims to be the reference in the computer-driven enzyme engineering market and convert molecular modelling in a commodity. In addition to our virtual enzyme sales (we plan to capture €11.17M by 2022 after entering into the North American market), we will promote a royalty-based revenue model from licensing enzymes developed in-house (global enzyme market is projected to reach €9B by 2024).
ZYMVOL’s founding team is composed by Maria Fátima Lucas, CEO, Emanuele Monza, CSO and Victor Gil, CTO. All members of the team hold a PhD in chemistry, physics and biomedical engineering.
The Company is seeing excellent traction which has allowed it to grown organically in its first 20 months. Thanks to a services-based business model it has already reached breakeven in 2018. The Company has quickly landed some high-profile business and developed a respected reputation by pioneering the access to high resolution computational simulations for all industries.
Biocatalysts are enzymes that accelerate industrial chemical reactions and have multiple applications for the synthesis of chemical compounds. Engineered enzymes can provide improved performance, representing a unique advantage. The protein engineering market is a fast-growing business estimated to reach 2.67B€ by 2024 (CARG +15%).
The main obstacle today to performance enhanced biocatalysts is that current enzyme engineering processes rely on slow and costly experimental tests with uncertain outcomes. Our in-silico engineering platform can rapidly find thousands of enzyme variants delivering reliable predictions, that allow to replace up to 90% of experimental tests, making the enzyme development cost (10-fold lower) and time (cut by 50%) effective.
ZYMVOL aims to be the reference in the computer-driven enzyme engineering market and convert molecular modelling in a commodity. In addition to our virtual enzyme sales (we plan to capture €11.17M by 2022 after entering into the North American market), we will promote a royalty-based revenue model from licensing enzymes developed in-house (global enzyme market is projected to reach €9B by 2024).
ZYMVOL’s founding team is composed by Maria Fátima Lucas, CEO, Emanuele Monza, CSO and Victor Gil, CTO. All members of the team hold a PhD in chemistry, physics and biomedical engineering.
The Company is seeing excellent traction which has allowed it to grown organically in its first 20 months. Thanks to a services-based business model it has already reached breakeven in 2018. The Company has quickly landed some high-profile business and developed a respected reputation by pioneering the access to high resolution computational simulations for all industries.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/873593 |
| Start date: | 01-10-2019 |
| End date: | 31-03-2022 |
| Total budget - Public funding: | 1 859 281,00 Euro - 1 301 496,00 Euro |
Cordis data
Original description
ZYMVOL is start-up specialized in computer-driven biocatalyst discovery and development for the pharmaceutical and fine chemical industry. We harness the power of high-performance computing to identify and optimize custom-made biocatalysts that deliver additional value.Biocatalysts are enzymes that accelerate industrial chemical reactions and have multiple applications for the synthesis of chemical compounds. Engineered enzymes can provide improved performance, representing a unique advantage. The protein engineering market is a fast-growing business estimated to reach 2.67B€ by 2024 (CARG +15%).
The main obstacle today to performance enhanced biocatalysts is that current enzyme engineering processes rely on slow and costly experimental tests with uncertain outcomes. Our in-silico engineering platform can rapidly find thousands of enzyme variants delivering reliable predictions, that allow to replace up to 90% of experimental tests, making the enzyme development cost (10-fold lower) and time (cut by 50%) effective.
ZYMVOL aims to be the reference in the computer-driven enzyme engineering market and convert molecular modelling in a commodity. In addition to our virtual enzyme sales (we plan to capture €11.17M by 2022 after entering into the North American market), we will promote a royalty-based revenue model from licensing enzymes developed in-house (global enzyme market is projected to reach €9B by 2024).
ZYMVOL’s founding team is composed by Maria Fátima Lucas, CEO, Emanuele Monza, CSO and Victor Gil, CTO. All members of the team hold a PhD in chemistry, physics and biomedical engineering.
The Company is seeing excellent traction which has allowed it to grown organically in its first 20 months. Thanks to a services-based business model it has already reached breakeven in 2018. The Company has quickly landed some high-profile business and developed a respected reputation by pioneering the access to high resolution computational simulations for all industries.
Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
